Selenium and lung cancer: A systematic review and meta analysis

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Fritz, Heidi ^a   Kennedy, Deborah ^a,b   Fergusson, Dean ^c   Fernandes, Rochelle ^a,b   Cooley, Kieran ^a,b   Seely, Andrew ^c   Sagar, Stephen ^d   Wong, Raimond ^d   Seely, Dugald ^a,c  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CISPLATIN; PLACEBO; SELENIUM; SELENOMETHIONINE; SODIUM SELENITE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HALITOSIS; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHEDEMA; MESOTHELIOMA; NAIL; NEPHROTOXICITY; NONHUMAN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); LUNG TUMOR; META ANALYSIS; METABOLISM;

CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; SELENIUM;

EID: 80455150179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026259     Document Type: Review

References (92)

1. American Cancer Society (2010) Cancer reference Information. What are the key statistics about lung cancer? www.cancer.org Accessed 30 April 2011.
2. Micke O, Buntzel J, Kisters K, Schafer U, Micke P, et al. (2010) Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon? Front Radiat Ther Oncol 42: 198-205.
3. Schrauzer GN, Surai PF, (2009) Selenium in human and animal nutrition: resolved and unresolved issues. A partly historical treatise in commemoration of the fiftieth anniversary of the discovery of the biological essentiality of selenium, dedicated to the memory of Klaus Schwarz (1914-1978) on the occasion of the thirtieth anniversary of his death. Crit Rev Biotechnol 29: 2-9.
4. Knizhnikov VA, Shandala NK, Komleva VA, Knyazhev VA, Tutelyan VA, (1996) The effect of dietary levels of selenium on radiation resistance and radiation-induced carcinogenesis. Nutrition Research 16: 505-516.
5. Muecke R, Schomburg L, Glatzel M, Berndt-Skorka R, Baaske D, et al. (2010) Multicenter, Phase 3 Trial Comparing Selenium Supplementation With Observation in Gynecologic Radiation Oncology. Int J Radiat Oncol Biol Phys.
6. Li D, Graef GL, Yee JA, Yan L, (2004) Dietary supplementation with high-selenium soy protein reduces pulmonary metastasis of melanoma cells in mice. J Nutr 134: 1536-1540.
7. Das A, Desai D, Pittman B, Amin S, El-Bayoumy K, (2003) Comparison of the chemopreventive efficacies of 1,4-phenylenebis(methylene)selenocyanate and selenium-enriched yeast on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mouse. Nutr Cancer 46: 179-185.
8. Zhuo H, Smith AH, Steinmaus C, (2004) Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 13: 771-778.
9. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 301: 39-51.
10. Navarro Silvera SA, Rohan TE, (2007) Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 18: 7-27.
11. Thomson CD, Chisholm A, McLachlan SK, Campbell JM, (2008) Brazil nuts: an effective way to improve selenium status. Am J Clin Nutr 87: 379-384.
12. Reid ME, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, et al. (2008) The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer 60: 155-163.
13. Larsen EH, Hansen M, Paulin H, Moesgaard S, Reid M, et al. (2004) Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. J AOAC Int 87: 225-232.
14. Rayman MP, Infante HG, Sargent M, (2008) Food-chain selenium and human health: spotlight on speciation. Br J Nutr 100: 238-253.
15. Rayman MP, (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64: 527-542.
16. Jablonska E, Gromadzinska J, Sobala W, Reszka E, Wasowicz W, (2008) Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr 47: 47-54.
17. Abdulah R, Miyazaki K, Nakazawa M, Koyama H, (2005) Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol 19: 141-150.
18. Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, et al. (2009) Methods of assessment of selenium status in humans: a systematic review. Am J Clin Nutr 89: 2025S-2039S.
19. Ip C, Dong Y, Ganther HE, (2002) New concepts in selenium chemoprevention. Cancer Metastasis Rev 21: 281-289.
20. Schrauzer GN, (2009) Selenium and selenium-antagonistic elements in nutritional cancer prevention. Crit Rev Biotechnol 29: 10-17.
21. Khan MA, Wang F, (2009) Mercury-selenium compounds and their toxicological significance: toward a molecular understanding of the mercury-selenium antagonism. Environ Toxicol Chem 28: 1567-1577.
22. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
23. Becker-Witt C, Weisshuhn TE, Ludtke R, Willich SN, (2003) Quality assessment of physical research in homeopathy. J Altern Complement Med 9: 113-132.
24. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, et al. (2006) Recommendations for reporting randomized controlled trials of herbal interventions: Explanation and elaboration. J Clin Epidemiol 59: 1134-1149.
25. Institute. OHR The Newcastle-Ottawa Scale (NOS). http://wwwohrica/programs/clinical_epidemiology/oxfordhtm Cited 24 September 2010.
26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
27. Witschi H, (2000) Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 26: 743-755.
28. Witschi H, Uyeminami D, Moran D, Espiritu I, (2000) Chemoprevention of tobacco-smoke lung carcinogenesis in mice after cessation of smoke exposure. Carcinogenesis 21: 977-982.
29. Schonberg SA, Rudra PK, Noding R, Skorpen F, Bjerve KS, et al. (1997) Evidence that changes in Se-glutathione peroxidase levels affect the sensitivity of human tumour cell lines to n-3 fatty acids. Carcinogenesis 18: 1897-1904.
30. Yu SY, Mao BL, Xiao P, Yu WP, Wang YL, et al. (1990) Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. Biol Trace Elem Res 24: 105-108.
31. Xu H, Mei W, Dong Z, Liao B, Study of the oxidative metabolic function and chemotaxis of neutrophils from patients with cancer influenced by Selenium Yeast.
32. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, et al. (1995) Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87: 497-505.
33. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS, (2001) Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1069-1076.
34. Ratnasinghe D, Tangrea JA, Forman MR, Hartman T, Gunter EW, et al. (2000) Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes Control 11: 129-135.
35. Menkes MS, Comstock GW, Vuilleumier JP, Helsing KJ, Rider AA, et al. (1986) Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 315: 1250-1254.
36. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276: 1957-1963.
37. Combs GF Jr, Clark LC, Turnbull BW, (1997) Reduction of cancer mortality and incidence by selenium supplementation. Med Klin (Munich) 92 (Suppl 3): 42-45.
38. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, et al. (2002) Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 11: 1285-1291.
39. Kamangar F, Qiao YL, Yu B, Sun XD, Abnet CC, et al. (2006) Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 15: 1562-1564.
40. Karp DD, Lee SJ, Shaw Wright GL, Johnson DH, Johnston MR, Goodman GE, Clamon GH, Okawara GS, Marks R, J. C. Ruckdeschel and MDACC Thoracic Chemoprevention Research Group. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings, 2010. 28 (18 suppl): CRA7004.
41. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, et al. (1997) The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biological Trace Element Research 56: 331-341.
42. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, et al. (2007) Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147: 217-223.
43. Vinceti M, Maraldi T, Bergomi M, Malagoli C, (2009) Risk of chronic low-dose selenium overexposure in humans: insights from epidemiology and biochemistry. Rev Environ Health 24: 231-248.
44. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630-639.
45. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, et al. (2004) A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18: 69-74.
46. Combs GF Jr, Clark LC, Turnbull BW, (1997) Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci 10: 227-234.
47. Vadgama JV, Wu Y, Shen D, Hsia S, Block J, (2000) Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Research 20: 1391-1414.
48. Li S, Zhou Y, Dong Y, Ip C, (2007) Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Research 27: 3075-3082.
49. Li S, Zhou Y, Wang R, Zhang H, Dong Y, et al. (2007) Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Molecular Cancer Therapeutics 6: 1031-1038.
50. Schroeder CP, Goeldner EM, Schulze-Forster K, Eickhoff CA, Holtermann P, et al. (2004) Effect of selenite combined with chemotherapeutic agents on the proliferation of human carcinoma cell lines. Biological Trace Element Research 99: 17-25.
51. Azrak RG, Frank CL, Ghadersohi A, Rustum YM, (2008) Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells. Cancer Biology and Therapy 7: 1901-1908.
52. Zhang Q, Azrak RG, (2009) The effect of methylseleninic acid on paclitaxel efficacy in A2780 ovarian cancer cells. Journal of Nanjing Medical University 23: 111-116.
53. Hu H, Jiang C, Ip C, Rustum YM, Lu J, (2005) Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clinical Cancer Research 11: 2379-2388.
54. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, et al. (2008) Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clinical Cancer Research 14: 1150-1158.
55. Gonzalez-Moreno O, Segura V, Serrano D, Nguewa P, De Las Rivas J, et al. (2007) Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo. International Journal of Cancer 121: 1197-1204.
56. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y, (1988) The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. British Journal of Cancer 58: 38-41.
57. Baldew GS, van den Hamer CJ, Los G, Vermeulen NP, de Goeij JJ, et al. (1989) Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Research 49: 3020-3023.
58. Vermeulen NP, Baldew GS, Los G, McVie JG, De Goeij JJ, (1993) Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds. Drug Metabolism & Disposition 21: 30-36.
59. Rao M, Rao MN, (1998) Protective effects of selenomethionine against cisplatin-induced renal toxicity in mice and rats. Journal of Pharmacy & Pharmacology 50: 687-691.
60. Caffrey PB, Frenkel GD, (2000) Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemotherapy & Pharmacology 46: 74-78.
61. Satoh M, Naganuma A, Imura N, (1992) Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice. Cancer Chemotherapy & Pharmacology 30: 439-443.
62. Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, et al. (2008) A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemotherapy & Pharmacology 62: 499-508.
63. Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, et al. (2006) A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clinical Cancer Research 12: 1237-1244.
64. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, et al. (2007) The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Nodgkin's lymphoma patients: Correlation with response and survival. Biological Trace Element Research 120: 1-10.
65. Bruns F, Buntzel J, Mucke R, Schonekaes K, Kisters K, et al. (2004) Selenium in the treatment of head and neck lymphedema. Medical Principles & Practice 13: 185-190.
66. Buntzel J, Weinaug R, Glatzel M, Frohlich D, Micke O, et al. (2002) Sodium selenite in the treatment of interstitial post-irradiation edema of the head and neck area. Trace Elements and Electrocytes 19: 33-37.
67. Micke O, Bruns F, Mucke R, Schafer U, Glatzel M, et al. (2003) Selenium in the treatment of radiation-associated secondary lymphedema. International Journal of Radiation Oncology, Biology, Physics 56: 40-49.
68. Micke O, Bruns F, Schafer U, Kisters K, Hesselmann S, et al. (2000) Selenium in the treatment of acute and chronic lymphedema. Trace Elements and Electrocytes 17: 206-209.
69. Zimmermann T, Leonhardt H, Kersting S, Albrecht S, Range U, et al. (2005) Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biological Trace Element Research 106: 193-203.
70. Elango N, Samuel S, Chinnakkannu P, (2006) Enzymatic and non-enzymatic antioxidant status in stage (III) human oral squamous cell carcinoma and treated with radical radio therapy: influence of selenium supplementation. Clinica Chimica Acta 373: 92-98.
71. Mucke R, Glatzel M, Riesenbeck D, Bernd-Skorka R, Seifert G, et al. (2004) Sodium selenite in gynecologic radiation oncology- First results of a phase III study. Trace Elements and Electrolytes 21: 78-82.
72. Buntzel J, Micke O, Mucke R, Glatzel M, Schonekaes KG, et al. (2005) Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer- Redox status data. Trace Elements and Electrolytes 22 (3): 211-215.
73. Mucke R, Glatzel M, Reichl B, Bernd-Skorka R, Buntzel J, et al. (2006) Sodium selenite in gynecologic radiation oncology: Results of a prospective randomized observation study. Trace Elements and Electrolytes 23: 173-177.
74. Buntzel J, Glatzel M, Kisters K, Mucke R, Bruns F, et al. (2006) Selenium as radioprotector in head and neck cancer patients- First clinical results. Trace Elements and Electrolytes 23: 178-180.
75. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E, (2009) Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect 117: 1409-1413.
76. Hu G, Cassano PA, (2000) Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Epidemiol 151: 975-981.
77. Mueller AS, Mueller K, Wolf NM, Pallauf J, (2009) Selenium and diabetes: an enigma? Free Radic Res pp. 1-31.
78. Finley JW, (2006) Bioavailability of selenium from foods. Nutr Rev 64: 146-151.
79. Ganther HE, (2001) Selenium metabolism and mechanisms of cancer prevention. Adv Exp Med Biol 492: 119-130.
80. Jackson MI, Combs GF Jr, (2008) Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11: 718-726.
81. Yamamoto N, Gupta A, Xu M, Miki K, Tsujimoto Y, et al. (2003) Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Ther 10: 445-450.
82. Swede H, Dong Y, Reid M, Marshall J, Ip C, (2003) Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture. Cancer Epidemiol Biomarkers Prev 12: 1248-1252.
83. Smith ML, Lancia JK, Mercer TI, Ip C, (2004) Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res 24: 1401-1408.
84. Li L, Xie Y, El-Sayed WM, Szakacs JG, Franklin MR, et al. (2005) Chemopreventive activity of selenocysteine prodrugs against tobacco-derived nitrosamine (NNK) induced lung tumors in the A/J mouse. J Biochem Mol Toxicol 19: 396-405.
85. El-Bayoumy K, Das A, Narayanan B, Narayanan N, Fiala ES, et al. (2006) Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer. Carcinogenesis 27: 1369-1376.
86. Tanaka T, Kohno H, Murakami M, Kagami S, El-Bayoumy K, (2000) Suppressing effects of dietary supplementation of the organoselenium 1,4-phenylenebis(methylene)selenocyanate and the Citrus antioxidant auraptene on lung metastasis of melanoma cells in mice. Cancer Res 60: 3713-3716.
87. El-Bayoumy K, Rose DP, Papanikolaou N, Leszczynska J, Swamy MV, et al. (2002) Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation. Int J Oncol 20: 557-561.
88. Prokopczyk B, Rosa JG, Desai D, Amin S, Sohn OS, et al. (2000) Chemoprevention of lung tumorigenesis induced by a mixture of benzo(a)pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by the organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Lett 161: 35-46.
89. Prokopczyk B, Amin S, Desai DH, Kurtzke C, Upadhyaya P, et al. (1997) Effects of 1,4-phenylenebis(methylene)selenocyanate and selenomethionine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mouse lung. Carcinogenesis 18: 1855-1857.
90. El-Bayoumy K, Upadhyaya P, Desai DH, Amin S, Hoffmann D, et al. (1996) Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Anticancer Res 16: 2709-2712.
91. El-Bayoumy K, Upadhyaya P, Desai DH, Amin S, Hecht SS, (1993) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis 14: 1111-1113.
92. Witschi H, Espiritu I, Suffia M, Pinkerton KE, (2002) Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 23: 289-294.